Uttarakhand Ban: Patanjali Cries Conspiracy

New Delhi : Patanjali Ayurveda has claimed that rules prohibiting advertisements of certain drugs do not apply to ayurvedic medicines and the Uttarakhand regulatory authority’s order asking the company to stop production of five drugs is part of a “conspiracy” by “an anti-ayurveda drug mafia”.

The claims challenge the position of the Uttarakhand Ayurveda and Unani Services Licensing Authority in the BJP-ruled state that had in a November 9 letter directed the company to stop producing five drugs it promoted as treatment for blood pressure, diabetes, goitre, glaucoma and high cholesterol.

The authority, citing complaints by Kerala-based doctor K.V. Babu, had asked Divya Pharmacy, Patanjali’s manufacturing unit, to halt production of BPgrit, Eyegrit, Lipidom, Madhugrit and Thyrogrit, submit revised label claims and seek fresh approval for each.

Babu had complained that the advertisements violated the Drugs and Cosmetics Act, 1940, and the Magic Remedies Act, 1954.

The Acts prohibit advertisements that promote prevention, treatment, or cure of certain disorders, including blood pressure, glaucoma, goitre, diabetes, liver disorders and heart disease.

Divya Pharmacy, in a media release on Thursday, said it had received no such letter or information from the department “in any form”.

It also said the drug rules do not apply to ayurvedic medicines.

“We will not allow this conspiracy to succeed in any way. (The) Ayurveda and Unani Services (licensing authority) Uttarakhand involved in this conspiracy, bypassed the departmental responsibility by writing the… letter on 09.11.2022”, and releasing it for the media, Divya Pharmacy said.

Divya Pharmacy said the licensing authority should “rectify its mistake and take appropriate action against the person who is involved in the conspiracy or the Patanjali Institute will take legal action against the people responsible for this conspiracy”.

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad